James A. Bristol, Ph.D. is Chairman of the Deciphera Board of Directors. Dr. Bristol worked for 32 years in drug discovery research and preclinical development at Schering-Plough Corporation, Parke-Davis and Pfizer Inc., serving in various senior research and development roles. From 2003 until his retirement in 2007, Dr. Bristol served as Senior Vice President of Worldwide Drug Discovery Research at Pfizer Global Research & Development, where he oversaw 3,000 scientists at 7 Pfizer sites as they produced an industry leading number of drug development candidates in 11 therapeutic areas. In 2009, Dr. Bristol joined Frazier Healthcare Ventures as a Senior Advisor. He has served as director of Ignyta, Inc. since 2014 and Cadent Therapeutics, Inc. since 2011. Dr. Bristol is the author of over 100 publications, abstracts and patents, and he conducted postdoctoral research at the University of Michigan (NIH Postdoctoral Fellow) and at The Squibb Institute for Medical Research. Dr. Bristol holds a Ph.D. in organic chemistry from the University of New Hampshire and a B.S. in Chemistry from Bates College.

Patricia L. Allen joined Zafgen as Chief Financial Officer in January 2013 until 2020 and serves as the Chair of the Audit Committee of the Deciphera Board of Directors. Ms. Allen has over 20 years of financial leadership experience in the biotechnology industry at both publicly traded and private companies. From 2011 to 2012, she provided independent consulting services to biotechnology companies in a variety of areas, including interim chief financial officer services, fundraising, deal structures, financial planning, organizational structure, investor relations and business development. Previously, from 2004 to 2011, Ms. Allen served as the Vice President of Finance, Treasurer and Principal Financial Officer of Alnylam Pharmaceuticals, Inc., a publicly traded biotechnology company. Prior to Alnylam, Ms. Allen was at Alkermes, Inc., a publicly traded biotechnology company, most recently as the Director of Finance. Ms. Allen began her career as an auditor at Deloitte & Touche, LLP. Ms. Allen graduated summa cum laude from Bryant College with a B.S. in business administration.

Frank S. Friedman currently serves as Chief Executive Officer at IPFS Inc., a privately-held finance company. Previously, Mr. Friedman worked for Deloitte Touche Tohmatsu Limited (Deloitte), a global services organization, from 1979 until his retirement from Deloitte in November 2019. During this time, Mr. Friedman served in several senior officer positions at Deloitte, including as the global Chief Operating Officer from June 2015 through June 2019. Mr. Friedman has also served as Deloitte’s U.S. Chief Operating Officer, from June 2015 to June 2017 and Deloitte’s U.S. Chief Financial Officer, from June 2011 through May 2016. Mr. Friedman served as interim U.S. Chief Executive Officer from 2014 to 2015. Mr. Friedman received his Bachelor of Arts in accounting and business administration from the University of Kansas.

Steven L. Hoerter is President and CEO of Deciphera Pharmaceuticals. Prior to joining Deciphera, Mr. Hoerter was Chief Commercial Officer at Agios Pharmaceuticals, Inc. where he built and led the team responsible for the commercialization of the company’s portfolio of first-in-class medicines for oncology and rare genetic diseases. Prior to joining Agios in 2016, Mr. Hoerter was Executive Vice President and Chief Commercial Officer at Clovis Oncology, Inc. Before joining Clovis, Mr. Hoerter was General Manager and Management Center Head at Roche for the Sub-Saharan Africa and Indian Ocean Region. From 2005 to 2010, he held a variety of positions at Genentech, Inc., including serving on the senior leadership team for Genentech’s BioOncology business. Prior to that, Mr. Hoerter held commercial roles at Chiron Corporation and Eli Lilly and Company in the U.S., Europe, and Africa. Mr. Hoerter currently serves on the Board of Directors at Constellation Pharmaceuticals, a biotechnology focused on developing novel therapeutics for patients with cancers associated with abnormal gene expression and was previously a member of the Board of Directors of Ignyta, Inc., a biotechnology company focused on precision medicine in oncology, until the company’s acquisition by Roche in 2017. Mr. Hoerter received his B.A. from Bucknell University, M.B.A. from Tilburg University in the Netherlands and M.S. in management from Purdue University.

John Martin has served as the CEO and President of Clinical Reference Laboratory. Mr. Martin has also served as President and Chief Executive Officer of CHC, Inc., the parent company of Clinical Reference Laboratory, since June 2016, in addition to serving as the Chairman of the Board of FormFox, Inc., another subsidiary of CHC, Inc., since August 2016. Prior to joining Clinical Reference Laboratory, Mr. Martin held senior executive roles with Viracor-IBT Laboratories, a clinical diagnostic laboratory specializing in infectious disease and immunology, first as its Chief Financial Officer and then as its President and Chief Executive Officer. Prior to Viracor, Mr. Martin was with George K. Baum & Company, where he served as Managing Director leading the firm’s middle market investment banking and strategic advisory practice. Mr. Martin’s career also includes 11 years in management roles with Sprint Corporation and General Electric. Mr. Martin holds a B.S. in Finance from Kansas State University.

Ron Squarer served as Chief Executive Officer and a member of the Board of Directors of Array BioPharma, Inc. (Array) from 2012 until its acquisition by Pfizer Inc. (Pfizer) in August 2019 following the successful commercial launches of both Braftovi® and Mektovi®. Before joining Array, Mr. Squarer held positions of increasing responsibility with Hospira, Inc., a global pharmaceutical and medical device company. As Senior Vice President and Chief Commercial Officer at Hospira, he was responsible for delivering $4 billion in annual revenue. Mr. Squarer joined Hospira from Mayne Pharma, where he served as Senior Vice President, Global Corporate and Business Development, when Mayne was sold to Hospira in 2007. Before Mayne Pharma, Mr. Squarer held leadership roles at both Pfizer (focused on oncology), and SmithKline Beecham Pharmaceuticals (now GlaxoSmithKline) in the U.S. and Europe. He currently serves as a member of the Board of Directors of Retrophin, Inc. and ADC Therapeutics SA. Mr. Squarer earned an M.B.A from the Kellogg School of Management, Northwestern University, and a bachelor’s degree in biochemistry from the University of California, Berkeley.

Dennis Walsh, CPA is Senior Vice President and Chief Financial Officer of Americo Life, Inc, a privately owned life insurance company.   Dennis was a partner with Walsh Washburn, LLC, a tax and finance consulting firm from 2003 to 2018.  He was previously employed by Americo as Controller and Tax Director from 1997 to 2003.  Mr. Walsh began his career with Touche Ross & Company, where he served in the tax department from 1988 to 1997.  Mr. Walsh holds a Masters in Accounting from the University of Missouri, Kansas City as well as a BSBA in Accounting from Rockhurst University and is a Certified Public Accountant.